MDGL vs. DRNA, RCKT, ICPT, YMAB, GBIO, ALNY, BMRN, NBIX, INCY, and UTHR
Should you be buying Madrigal Pharmaceuticals stock or one of its competitors? The main competitors of Madrigal Pharmaceuticals include Dicerna Pharmaceuticals (DRNA), Rocket Pharmaceuticals (RCKT), Intercept Pharmaceuticals (ICPT), Y-mAbs Therapeutics (YMAB), Generation Bio (GBIO), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), Incyte (INCY), and United Therapeutics (UTHR). These companies are all part of the "medical" sector.
Dicerna Pharmaceuticals (NASDAQ:DRNA) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, community ranking, valuation, dividends and risk.
Madrigal Pharmaceuticals has a net margin of 0.00% compared to Madrigal Pharmaceuticals' net margin of -64.53%. Madrigal Pharmaceuticals' return on equity of -103.08% beat Dicerna Pharmaceuticals' return on equity.
Dicerna Pharmaceuticals has higher revenue and earnings than Madrigal Pharmaceuticals. Dicerna Pharmaceuticals is trading at a lower price-to-earnings ratio than Madrigal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
78.9% of Dicerna Pharmaceuticals shares are held by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 10.2% of Dicerna Pharmaceuticals shares are held by insiders. Comparatively, 23.9% of Madrigal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Dicerna Pharmaceuticals has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of -0.33, suggesting that its stock price is 133% less volatile than the S&P 500.
Madrigal Pharmaceuticals has a consensus price target of $345.09, suggesting a potential upside of 46.13%. Given Dicerna Pharmaceuticals' higher probable upside, analysts plainly believe Madrigal Pharmaceuticals is more favorable than Dicerna Pharmaceuticals.
In the previous week, Madrigal Pharmaceuticals had 7 more articles in the media than Dicerna Pharmaceuticals. MarketBeat recorded 7 mentions for Madrigal Pharmaceuticals and 0 mentions for Dicerna Pharmaceuticals. Dicerna Pharmaceuticals' average media sentiment score of 1.23 beat Madrigal Pharmaceuticals' score of 0.00 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media.
Dicerna Pharmaceuticals received 4 more outperform votes than Madrigal Pharmaceuticals when rated by MarketBeat users. However, 68.60% of users gave Madrigal Pharmaceuticals an outperform vote while only 62.88% of users gave Dicerna Pharmaceuticals an outperform vote.
Summary
Madrigal Pharmaceuticals beats Dicerna Pharmaceuticals on 9 of the 16 factors compared between the two stocks.
Get Madrigal Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for MDGL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MDGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Madrigal Pharmaceuticals Competitors List
Related Companies and Tools
